Hospital Erasto Gaertner Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2006
NCT00419081
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Hospital Erasto Gaertner | Hospital Erasto Gaertner/ Liga Paranaense de Combate ao Cancer | Hospital Erasto Gaertner - Liga Paranaense de Combate ao Cancer - CEPEP

Active Ingredients

Drugs in Phase 2 Trials (1)

forodesine (1 trial)

Drugs in Other Trials (2)

dexamethasone (1 trial)

nandrolone phenpropionate (Durabolin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Lymphoma (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 3